Payment overview · 2025
General Payments
$155.06
7 reported records · 3 companies
Healthcare provider profile · identity verified
Laura E Glueck, DO
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, MO · NPI 1457611261
Verified facts
What the public records show
CMS Open Payments records show Laura E Glueck, DO received $155.06 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 66.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Viberzi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.33 | 66.6% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.88 | 20.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.85 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $155.06 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $103.33 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1085 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 815 | 122 |
| Furosemide | Furosemide | 707 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 566 | 128 |
| Lisinopril | Lisinopril | 539 | 127 |
| Eliquis | Apixaban | 502 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 498 | 87 |
| Gabapentin | Gabapentin | 449 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 416 | 58 |
| Losartan Potassium | Losartan Potassium | 355 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 275 | 23 |
| Lorazepam | Lorazepam | 272 | 45 |
| Famotidine | Famotidine | 268 | 31 |
| Potassium Chloride | Potassium Chloride | 251 | 43 |
| Montelukast Sodium | Montelukast Sodium | 245 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 51 |
| Donepezil Hcl | Donepezil Hcl | 238 | 35 |
| Omeprazole | Omeprazole | 233 | 60 |
| Sertraline Hcl | Sertraline Hcl | 232 | 41 |
| Trazodone Hcl | Trazodone Hcl | 228 | 38 |
| Alendronate Sodium | Alendronate Sodium | 223 | 50 |
| Carvedilol | Carvedilol | 216 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 30 |
| Metformin Hcl | Metformin Hcl | 206 | 67 |
| Mirtazapine | Mirtazapine | 206 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 201 | 59 |
| Memantine Hcl | Memantine Hcl | 196 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 179 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 174 | 28 |
| Tramadol Hcl | Tramadol Hcl | 163 | 41 |
| Buspirone Hcl | Buspirone Hcl | 157 | 24 |
| Jardiance | Empagliflozin | 153 | 25 |
| Simvastatin | Simvastatin | 147 | 40 |
| Xarelto | Rivaroxaban | 142 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 136 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 122 | 122 |
| Lamotrigine | Lamotrigine | 120 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 112 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 35 |
| Pregabalin | Pregabalin | 106 | 20 |
| Lovastatin | Lovastatin | 105 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 19 |
| Allopurinol | Allopurinol | 100 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 97 | 15 |
| Baclofen | Baclofen | 93 | 16 |
| Ozempic | Semaglutide | 92 | 17 |
| Januvia | Sitagliptin Phosphate | 91 | suppressed |
| Bupropion Xl | Bupropion Hcl | 88 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 17 |
| Myrbetriq | Mirabegron | 88 | suppressed |
| Alprazolam | Alprazolam | 87 | 16 |
| Meloxicam | Meloxicam | 85 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 80 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | suppressed |
| Glipizide | Glipizide | 73 | 18 |
| Tradjenta | Linagliptin | 68 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 67 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 64 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 58 | suppressed |
| Levetiracetam | Levetiracetam | 58 | 12 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Torsemide | Torsemide | 53 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 12 |
| Celecoxib | Celecoxib | 50 | 13 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Mounjaro | Tirzepatide | 46 | 11 |
| Finasteride | Finasteride | 45 | 15 |
| Latanoprost | Latanoprost | 45 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 45 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 45 | 45 |
| Atenolol | Atenolol | 44 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 17 |
| Spironolactone | Spironolactone | 43 | 15 |
| Diazepam | Diazepam | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Entacapone | Entacapone | 40 | suppressed |
| Phenobarbital | Phenobarbital | 40 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | 11 |
| Linzess | Linaclotide | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Phenytoin | Phenytoin | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Nystatin | Nystatin | 30 | 19 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Anastrozole | Anastrozole | 29 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Azithromycin | Azithromycin | 25 | 23 |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Prednisone | Prednisone | 25 | 20 |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Clonidine | Clonidine | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Viberzi | Eluxadoline | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Darunavir | Darunavir | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Trimethoprim | Trimethoprim | 18 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $155.06 · 7 records | ABBVIE INC. | Dexcom G6 Transmitter, Ozempic, Rybelsus, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error